ICON8事后探索性分析:卵巢癌新辅助化疗的RECIST与CA125缓解
ICON8是一项国际多中心随机3期试验,本事后探索性分析纳入779例计划接受新辅助化疗后延迟初次手术的上皮性卵巢癌患者。在564例可评估RECIST的患者中,348例(62%)达到完全或部分缓解;在727例可评估GCIG CA125的患者中,610例(84%)达到CA125缓解。
要点
- RECIST客观缓解率为62%,低于临床常告知患者的比例
- 不应仅因缺乏RECIST或CA125缓解而拒绝手术
核心结论
- RECIST定义的影像学缓解率低于临床常引用的数值。
- RECIST和GCIG CA125缓解不应作为个体预测标志物来分层筛选可能从延迟初次手术中获益的患者。
- 不应仅因缺乏RECIST或GCIG CA125缓解而拒绝患者手术。
研究设计与样本
- ICON8为国际多中心随机3期试验,在英国、澳大利亚、新西兰、墨西哥、韩国和爱尔兰的117家医院开展。
- 本分析为事后探索性分析,仅纳入计划接受新辅助化疗后延迟初次手术且具有RECIST和/或GCIG CA125可评估疾病的患者。
- 共1566例女性入组ICON8,其中779例(50%)计划接受新辅助化疗后延迟初次手术。
- 随机分配为1:1:1至三组:组1为卡铂(AUC5或AUC6)联合紫杉醇175 mg/m2每21天第1天;组2为卡铂(AUC5或AUC6)第1天联合剂量分割紫杉醇80 mg/m2第1、8、15天;组3为剂量分割卡铂(AUC2)联合剂量分割紫杉醇80 mg/m2第1、8、15天。
- 化疗最多允许6个周期。
主要发现
- 564例入组时有RECIST可评估疾病的患者中,348例(62%)达到完全或部分缓解。
- 727例诊断时可评估GCIG CA125的患者中,610例(84%)达到CA125缓解。
- RECIST完全或部分缓解者中335例有187例(56%)达到完全细胞减灭(R0),疾病稳定者172例中73例(42%)达到R0;CA125缓解者576例中290例(50%)达到R0,无缓解者101例中30例(30%)达到R0。
关键数值与推荐
- RECIST完全或部分缓解率62%(348/564)。
- GCIG CA125缓解率84%(610/727)。
- RECIST缓解者R0率56%(187/335),疾病稳定者42%(73/172);CA125缓解者R0率50%(290/576),无缓解者30%(30/101)。
临床怎么用
- RECIST和GCIG CA125缓解应结合患者临床手术耐受能力综合评估,而非单独用于分层。
- 不应仅因缺乏RECIST或GCIG CA125缓解而拒绝患者接受延迟初次手术。
- 临床告知患者新辅助化疗缓解率时,应参考RECIST客观缓解率而非更高的常引数值。
局限性
- 本分析为事后探索性分析,非预设主要分析。
- 无进展生存期采用landmark方法,定义与ICON8意向治疗主要分析不同。
- 患者和临床医生未对分组设盲。
- 手术时机和新辅助化疗使用由当地多学科病例审查决定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been validated in randomised, phase 3 trials, evaluation of response to neoadjuvant chemotherapy using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST), and cancer antigen 125 (CA125) has not been reported. We describe RECIST and Gynecologic Cancer InterGroup (GCIG) CA125 responses in patients receiving platinum-based neoadjuvant chemotherapy followed by DPS in the ICON8 trial. METHODS: ICON8 was an international, multicentre, randomised, phase 3 trial done across 117 hospitals in the UK, Australia, New Zealand, Mexico, South Korea, and Ireland. The trial included women aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, life expectancy of more than 12 weeks, and newly diagnosed International Federation of Gynecology and Obstetrics (FIGO; 1988) stage IC-IIA high-grade serous, clear cell, or any poorly differentiated or grade 3 histological subtype, or any FIGO (1988) stage IIB-IV epithelial cancer of the ovary, fallopian tube, or primary peritoneum. Patients were randomly assigned (1:1:1) to receive intravenous carboplatin (area under the curve [AUC]5 or AUC6) and intravenous paclitaxel (175 mg/m2 by body surface area) on day 1 of every 21-day cycle (control group; group 1); intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose-fractionated paclitaxel (80 mg/m2 by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 2); or intravenous dose-fractionated carboplatin (AUC2) and intravenous dose-fractionated paclitaxel (80 mg/m2 by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 3). The maximum number of cycles of chemotherapy permitted was six. Randomisation was done with a minimisation method, and patients were stratified according to GCIG group, disease stage, and timing and outcome of cytoreductive surgery. Patients and clinicians were not masked to group allocation. The scheduling of surgery and use of neoadjuvant chemotherapy were determined by local multidisciplinary case review. In this post-hoc exploratory analysis of ICON8, progression-free survival was analysed using the landmark method and defined as the time interval between the date of pre-surgical planning radiological tumour assessment to the date of investigator-assessed clinical or radiological progression or death, whichever occurred first. This definition is different from the intention-to-treat primary progression-free survival analysis of ICON8, which defined progression-free survival as the time from randomisation to the date of first clinical or radiological progression or death, whichever occurred first. We also compared the extent of surgical cytoreduction with RECIST and GCIG CA125 responses. This post-hoc exploratory analysis includes only women recruited to ICON8 who were planned for neoadjuvant chemotherapy followed by DPS and had RECIST and/or GCIG CA125-evaluable disease. ICON8 is closed for enrolment and follow-up, and registered with ClinicalTrials.gov, NCT01654146. FINDINGS: Between June 6, 2011, and Nov 28, 2014, 1566 women were enrolled in ICON8, of whom 779 (50%) were planned for neoadjuvant chemotherapy followed by DPS. Median follow-up was 29·5 months (IQR 15·6-54·3) for the neoadjuvant chemotherapy followed by DPS population. Of 564 women who had RECIST-evaluable disease at trial entry, 348 (62%) had a complete or partial response. Of 727 women who were evaluable by GCIG CA125 criteria at the time of diagnosis, 610 (84%) had a CA125 response. Median progression-free survival was 14·4 months (95% CI 9·2-28·0; 297 events) for patients with a RECIST complete or partial response and 13·3 months (8·1-20·1; 171 events) for those with RECIST stable disease. Median progression-free survival for women with a GCIG CA125 response was 13·8 months (95% CI 8·8-23·4; 544 events) and 9·7 months (5·8-14·5; 111 events) for those without a GCIG CA125 response. Complete cytoreduction (R0) was achieved in 187 (56%) of 335 women with a RECIST complete or partial response and 73 (42%) of 172 women with RECIST stable disease. Complete cytoreduction was achieved in 290 (50%) of 576 women with a GCIG CA125 response and 30 (30%) of 101 women without a GCIG CA125 response. INTERPRETATION: The RECIST-defined radiological response rate was lower than that frequently quoted to patients in the clinic. RECIST and GCIG CA125 responses to neoadjuvant chemotherapy for epithelial ovarian cancer should not be used as individual predictive markers to stratify patients who are likely to benefit from DPS, but instead used in conjunction with the patient's clinical capacity to undergo cytoreductive surgery. A patient should not be denied surgery based solely on the lack of a RECIST or GCIG CA125 response. FUNDING: Cancer Research UK, UK Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, and Cancer Australia.
引用
- Morgan RD, McNeish IA, Cook AD, et al. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol. 2020. PMID: 33357510. doi:10.1016/S1470-2045(20)30591-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。